Andrew Sassine - Gemphire Therapeutics Independent Director
Director
Mr. Andrew Sassine is an Independent Director of the Company. Mr. Sassine served in various positions at Fidelity Investments from 1999 to 2012, including as a Portfolio Manager for various funds from 2005 to December 2011. Mr. Sassine has also served on several boards of life science companies. Mr. Sassine currently serves on the board of directors of iCAD, Inc., a public cancer detection and radiation therapy solutions company and previously served on the boards of directors of FluoroPharma Medical, Inc., a public biopharmaceutical company, Acorn Energy, Inc., a public holding company focused on technology solutions for energy infrastructure asset management and CNS Response, Inc., a public psychiatric clinical decision support company. Mr. Sassine also serves on the board of directors of Freedom Meditech, Inc., a private medical device company, and Comhear Inc., a private digital audio software and device company, where he is also the chairman of the board of directors. Mr. Sassine serves on the Strategic Advisory Board of MD Revolution Inc., a private digital health service company. Mr. Sassine was a member of the Henry B. Tippie College of Business, University of Iowa Board of Advisors since 2009 and served on the board of trustees at the Clarke Schools for Hearing and Speech from 2009 through 2014 since 2015.
Age | 54 |
Tenure | 9 years |
Professional Marks | MBA |
Phone | 734-245-1700 |
Web | http://www.gemphire.com |
Gemphire Therapeutics Management Efficiency
The company has return on total asset (ROA) of (44.9) % which means that it has lost $44.9 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (280.97) %, meaning that it created substantial loss on money invested by shareholders. Gemphire Therapeutics' management efficiency ratios could be used to measure how well Gemphire Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Rodrigo Kirberg | Compania Cervecerias Unidas | 54 | |
Caroline Tsay | The Coca Cola | 39 | |
Rate Margareta | Vindicator Silver Lead Mining | 37 | |
Howard Buffett | The Coca Cola | 60 | |
Didier Debrosse | Compania Cervecerias Unidas | 59 | |
Helene Gayle | The Coca Cola | 65 | |
Robert Kotick | The Coca Cola | 57 | |
Alexis Herman | The Coca Cola | 73 | |
Manuel Eyzaguirre | Compania Cervecerias Unidas | N/A | |
Cecil Conlee | National Beverage Corp | 80 | |
Alvaro Rio | Compania Cervecerias Unidas | N/A | |
Jose Westerflier | Compania Cervecerias Unidas | 56 | |
Jose Mackenna | Compania Cervecerias Unidas | 63 | |
Philippe Pasquet | Compania Cervecerias Unidas | 75 | |
Richard Daley | The Coca Cola | 75 | |
David Weinberg | The Coca Cola | 69 | |
Herbert Allen | The Coca Cola | 53 | |
Samuel Hathorn | National Beverage Corp | 73 | |
Ana OShea | The Coca Cola | 61 | |
Christopher Davis | The Coca Cola | 55 | |
Rory Cullinan | Compania Cervecerias Unidas | 60 |
Management Performance
Return On Equity | -280.97 | |||
Return On Asset | -44.9 |
Gemphire Therapeutics Leadership Team
Elected by the shareholders, the Gemphire Therapeutics' board of directors comprises two types of representatives: Gemphire Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gemphire. The board's role is to monitor Gemphire Therapeutics' management team and ensure that shareholders' interests are well served. Gemphire Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gemphire Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Charles Bisgaier, Co-Founder, Chief Scientific Officer | ||
Mina Sooch, President CEO | ||
Kenneth Kousky, Independent Director | ||
Andrew Sassine, Independent Director | ||
Jeffrey Mathiesen, CFO | ||
Seth Reno, Chief Commercial Officer | ||
Pedro Lichtinger, Independent Director | ||
Steven Gullans, Interim President Interim CEO, Director | ||
David Lowenschuss, Co-Founder, Chief Legal Officer | ||
Kent Hawryluk, Independent Director | ||
Lee Golden, Chief Medical Officer |
Gemphire Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Gemphire Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -280.97 | |||
Return On Asset | -44.9 | |||
Current Valuation | 109.69 M | |||
Shares Outstanding | 14.87 M | |||
Shares Owned By Insiders | 55.90 % | |||
Shares Owned By Institutions | 17.95 % | |||
Number Of Shares Shorted | 142.79 K | |||
Price To Earning | (2.89) X | |||
Price To Book | 2.46 X | |||
EBITDA | (12.09 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Gemphire Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Gemphire Therapeutics' short interest history, or implied volatility extrapolated from Gemphire Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Consideration for investing in Gemphire Stock
If you are still planning to invest in Gemphire Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gemphire Therapeutics' history and understand the potential risks before investing.
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Stocks Directory Find actively traded stocks across global markets | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |